In vitro validation of anticancer drug combinations on colon cancer cell lines SW620 and HCT116
MetadataShow full item record
Combinatory drug treatment, e.g. targeting different proteins in specific signaling pathways tailored to an individual’s tumor, is expected to overcome problems related to individual variation in drug efficacy, resistance and side effect. However, our knowledge about beneficial drug combinations is still limited due to the large number of possible drug targets and the tumor diversity. Our research group performed a high throughput screening on multiple cell line to discover synergetic drug combinations on viability. The high throughput screening showed that SW620 cells treated with the inhibitor combination CT+D1 and PI+D1 were synergistic. The aim of this study was to evaluate and characterize the effect of specific inhibitor combinations initially observed by high throughput screening further and to study the effect of these combinations on another CRC cell line. We found that the inhibitor combination CT+D1 showed synergetic effect on apoptosis and cell death in the SW620 cell line. In addition, PI+D1 showed synergetic effect on decreased proliferation. These finding were corresponding to the high throughput screening. The inhibitor combination CT+D1 was also synergetic in the HCT116 cell line.